If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
For a fixed mass of an ideal gas kept at a fixed temperature, pressure and volume are inversely proportional. Boyle's law is a gas law, stating that the pressure and volume of a gas have an inverse relationship. If volume increases, then pressure decreases and vice versa, when the temperature is held constant. Therefore, when the volume is halved, the pressure is doubled; and if the volume is doubled, the pressure is halved.
=== East Africa === Italy joined the war on Germany's side on 10 June 1940, opening the East African Campaign and the Desert War in North Africa. A Rhodesian-led force of irregulars from the Somaliland Camel Corps—based in British Somaliland, on the Horn of Africa's north coast—took part in one of the first clashes between British and Italian forces when it exchanged fire with an Italian banda (irregular company) around dawn on 11 June. Two days later three Caproni bombers of the Regia Aeronautica attacked Wajir, one of No. 237 Squadron's forward airstrips, damaging two Rhodesian aircraft.
Cells in all organisms regulate gene expression by turnover of gene transcripts (single stranded RNA): The amount of an expressed gene in a cell can be measured by the number of copies of an RNA transcript of that gene present in a sample. In order to robustly detect and quantify gene expression from small amounts of RNA, amplification of the gene transcript is necessary. The polymerase chain reaction (PCR) is a common method for amplifying DNA; for RNA-based PCR the RNA sample is first reverse-transcribed to complementary DNA (cDNA) with reverse transcriptase. In order to amplify small amounts of DNA, the same methodology is used as in conventional PCR using a DNA template, at least one pair of specific primers, deoxyribonucleotide triphosphates, a suitable buffer solution and a thermo-stable DNA polymerase. A substance marked with a fluorophore is added to this mixture in a thermal cycler that contains sensors for measuring the fluorescence of the fluorophore after it has been excited at the required wavelength allowing the generation rate to be measured for one or more specific products. This allows the rate of generation of the amplified product to be measured at each PCR cycle. The data thus generated can be analysed by computer software to calculate relative gene expression (or mRNA copy number) in several samples. Quantitative PCR can also be applied to the detection and quantification of DNA in samples to determine the presence and abundance of a particular DNA sequence in these samples.
Charles Edward Moody, Deputy Chief Executive, Engineering and Marine Training Authority. For services to Training. Derek William Charles Morgan. For public service in Wales. Patricia Morris. For political service. John Robin Mulholland, Agricultural Estates Manager, Crown Estate Commissioners. Herbert Neville Nahapiet, Chief Executive, UK Detention Services. For services to Engineering and to the Construction Industry. Robert Livingston Nelson, Director, Dounreay, UKAEA. For services to the Nuclear Industry. Malcolm Terence Newman, Range E, Her Majesty's Treasury Joan Mary North. For political and public service Jean Nugent, Nursing Director, St. Helier Hospital, Carshalton, Surrey. For services to Health Care. Geoffrey James Osborne, lately Grade 7, Department of the Environment. Alfred David Owen, Trustee, Community Development Foundation. For services to the community in the West Midlands. Anthony Frederick Parker, lately Courts Administrator, Lord Chancellor's Department. Pamela Margaret Parker, Vice President, All England Women's Hockey Association. For services to Hockey. Alan Edward Parkinson, Officer in Charge, Board of Inland Revenue. David Romer Paton. For services to the community in Aberdeen. Professor Christopher Charles Payne, Chief Executive, Horticulture Research International. For services to Horticultural Research. Ann Philippa Pearce (Mrs Christie), Author. For services to Children's Literature. Anne Pegington, Secretary, Royal College of Nursing's Welsh Board. For services to Nursing in Wales. Howard Wesley Petch, Principal, Bishop Burton College.
At some point in his reign a widespread uprising occurred, a large coalition of city-states led by Iphur-Kis of Kish (Sumer) and Amar-Girid of Uruk, joined by Enlil-nizu of Nippur, and including the city-states of "Kutha, TiWA, Sippar, Kazallu, Kiritab, [Api]ak and GN" as well as "Amorite [hi]ghlanders". The rebellion was joined by the city of Borsippa, among others. We know of these events from a number of Old Babylonian copies of earlier inscriptions as well as one contemporary record from the Old Akkadian period. The Bassetki Statue, discovered in 1974, was the base of a life-sized copper statue of Naram-Sin. It reads:
Sources: en.wikipedia.org
President Donald Trump has stated the goals of the war were to destroy Iran's ballistic missiles, eliminate their navy, prevent them from acquiring nuclear weapons, and to stop Iranian proxies from holding power. Trump asserted that Iran's ballistic missile program could endanger US allies "throughout the world", including Europe and American mainland. Pete Hegseth said that Iran would be capable of nuclear blackmail with their ballistic missiles if the US did not attack it. However, a Defense Intelligence Agency assessment determined that Iran would not be capable of building intercontinental ballistic missiles until 2035. Secretary of State Marco Rubio warned that Iran posed an "imminent threat" to US bases in the event of Israeli strikes on Iran, thereby portraying the war as a preemptive one. Mike Johnson, the Speaker of the United States House of Representatives and Rubio said that Israel was going to attack Iran, after which Iran's retaliations against US bases would have brought them into war anyway. Senator Mark Warner of the Senate Intelligence Committee who was briefed by Rubio before the war began said that there was no evidence that Iran was going to launch a pre-emptive strike against the US, and that the war was ultimately decided upon by Israel. Trump rejected these claims, stating that "I might have forced their hands.
Under pressure from religious entities, Lula created a Department of Support for Therapeutic Communities aimed at the treatment of chemically dependent people. After the measure was criticized by organizations linked to human rights, the Ministry of Development and Social Assistance, Family and Fight Against Hunger announced that it would review the decision. The Brazilian Mental Health Association had also spoken out against the measure in a note of repudiation.
=== Preclinical development === Several ASOs are currently being investigated in disease models for Alexander disease, ATXN2 (gene) and FUS (gene) amyotrophic lateral sclerosis, Angelman syndrome, Lafora disease, lymphoma, multiple myeloma, myotonic dystrophy, Parkinson's disease, Pelizaeus–Merzbacher disease, and prion disease, Rett syndrome, spinocerebellar Ataxia Type 3.
== Deactivation == As with other G protein-coupled receptors, signalling by the μ-opioid receptor is terminated through several different mechanisms, which are upregulated with chronic use, leading to rapid tachyphylaxis. The most important regulatory proteins for the MOR are the β-arrestins arrestin beta 1 and arrestin beta 2, and the RGS proteins RGS4, RGS9-2, RGS14, and RGSZ2. Long-term or high-dose use of opioids may also lead to additional mechanisms of tolerance becoming involved. This includes downregulation of MOR gene expression, so the number of receptors presented on the cell surface is actually reduced, as opposed to the more short-term desensitisation induced by β-arrestins or RGS proteins. Another long-term adaptation to opioid use can be upregulation of glutamate and other pathways in the brain which can exert an opioid-opposing effect, so reduce the effects of opioid drugs by altering downstream pathways, regardless of MOR activation.
Sources: en.wikipedia.org
The eighth generation was released for the Japanese domestic market in June 1994 with front-wheel drive. The saloon version was again sold as the "Mazda Protegé" in North America, as the Mazda Artis in some South American markets, as the "Mazda Étude" in South Africa and as Mazda Allegro in Colombia. Originally there was a three-door coupé (323C/Familia Neo) available, but after sluggish sales, a hatchback version based on the facelifted Familia saloon replaced it. This generation grew considerably, with the four-door saloon's wheelbase only 5 millimetres short of the then-current Mazda 626, a mid-size car. The car was not originally offered with a 1.3-litre engine in Japan, with the lineup beginning with the bigger 1.5-litre. To close this gap in the lineup, the BG hatchback with the 1.3-litre engine was kept available until October 1996, when the new hatchback model was introduced (323P) and the smaller engine was made available. An unusual JDM station wagon model appeared in September 1994, with the discontinuation of the 1985-generation station wagon. The Mazda Familia Van offered after this year was a rebadged Nissan AD/Wingroad/Sunny California, which was essentially the station wagon version of the Nissan Sunny/Sentra/Pulsar (N14). A new model appeared in the same month, when a lean-burn version called the GS-L arrived: its Z5-DEL engine produces 94 PS (69 kW), three down on the regular Z5-DE, but gas mileage improved by ten to fifteen percent. Another loan was the 1.7-litre intercooled turbo-diesel engine purchased from Isuzu for use in saloons since October 1994.
=== Techniques to isolate specific genes === Gene identification can be accomplished using computer-based methods known as heterologous screening techniques. A digital library of cDNA sequences has data from many sequencing projects and allows for easy access to sequence information for known genes. If a genomic sequence is unknown or unavailable, DNA undergoes a process of random fragmentation, cloning, and screening to determine its phenotype. Although various methods can be used to obtain a particular gene, the easiest way to reveal the components of an unknown DNA sequence is by first identifying its restriction enzymes. Restriction enzymes are enzymes responsible for cleaving DNA into fragments at a specific site within molecules known as restriction sites. These enzymes can be located in bacteria or archaea and are known to protect DNA from foreign invasion of viruses. Restriction enzymes are distinct, and each recognizes only a specific sequence of base pairs within DNA, many of which tend to be palindromic. By locating each enzyme, the sequence associated with the restriction enzyme can be identified and isolated. If the sequence is known, a technique referred to as the Polymerase chain reaction (PCR) can be used to isolate a gene of interest. The purpose of PCR is to not only identify but to amplify a particular DNA segment through phases of denaturation, annealing, and extension. Denaturation places a double-stranded DNA template in high-temperature conditions of 95 °C to break its weak hydrogen bonds and enforce strand separation.
Remineralisation of tooth enamel involves the reintroduction of mineral ions into demineralised enamel. Hydroxyapatite is the main mineral component of enamel in teeth. During demineralisation, calcium and phosphorus ions are drawn out from the hydroxyapatite. The mineral ions introduced during remineralisation restores the structure of the hydroxyapatite crystals. When fluoride ions are present during the remineralisation process, either through water fluoridation or the use of fluoride-containing toothpaste, the stronger and more acid-resistant fluorapatite crystals form instead of hydroxyapatite crystals.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.